KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.

Oxid Med Cell Longev · 2022 · PMC9893523 · PMID 36742345

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

According to pathological stages, KIF11 expression showed a trend variation along with the disease progression in ACC, BLCA, LIHC, LUAD, SKCM, BRCA, KIRC, KIRP, LUSC, and UCEC ( Figure 3(a) ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.